Document is current
Any future updates will be listed below
-
Authors
Lerma-Martin, Celia https://orcid.org/0000-0003-4201-0816
Badia-i-Mompel, Pau https://orcid.org/0000-0002-1004-3923
Ramirez Flores, Ricardo O. https://orcid.org/0000-0003-0087-371X
Sekol, Patricia https://orcid.org/0000-0001-5776-5272
Schäfer, Philipp S. L. https://orcid.org/0009-0008-4403-8592
Riedl, Christian J.
Hofmann, Annika
Thäwel, Thomas
Wünnemann, Florian
Ibarra-Arellano, Miguel A. https://orcid.org/0000-0001-8411-4854
Trobisch, Tim
Eisele, Philipp
Schapiro, Denis https://orcid.org/0000-0002-9391-5722
Haeussler, Maximilian
Hametner, Simon
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Schirmer, Lucas https://orcid.org/0000-0001-7142-4116
- License Information
-
More Information
Article History
Received: 23 October 2022
Accepted: 30 September 2024
First Online: 5 November 2024
Competing interests
: P.E. has received travel expenses from Bayer Health Care. D.S. reports funding from Cellzome, a GSK company and received honorariums from Immunai, Noetik, Alpenglow and Lunaphore. J.S.-R. reports funding from GSK, Pfizer and Sanofi and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Owkin, Moderna, Pfizer and Grunenthal. L.S. reports research support from Roche and Merck and filed a patent for the detection of antibodies against KIR4.1 in a subpopulation of patients with multiple sclerosis (WO2015166057A1). The remaining authors declare no competing interests.
